Endo Operations Drug Patent Portfolio
Endo Operations owns 12 orange book drugs protected by 78 US patents with Supprelin La having the least patent protection, holding only 1 patent. And Sumavel Dosepro with maximum patent protection, holding 16 patents. Given below is the list of Endo Operations's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10869845 | Ephedrine compositions and methods | 22 Jan, 2040 | Active |
| US12029710 | Ephedrine compositions and methods | 22 Jan, 2040 | Active |
| US10653646 | Epinephrine compositions and containers | 21 Mar, 2039 | Active |
| US11083698 | Epinephrine compositions and containers | 21 Mar, 2039 | Active |
| US11207280 | Epinephrine compositions and containers | 21 Mar, 2039 | Active |
| US12133837 | 21 Mar, 2039 | Active | |
| US10130592 | Epinephrine formulations | 13 Mar, 2035 | Active |
| US9119876 | Epinephrine formulations | 13 Mar, 2035 | Active |
| US9295657 | Epinephrine formulations | 13 Mar, 2035 | Active |
| US10010575 | Vasopressin formulations for use in treatment of hypotension | 30 Jan, 2035 | Active |
| US9375478 | Vasopressin formulations for use in treatment of hypotension | 30 Jan, 2035 | Active |
| US9687526 | Vasopressin formulations for use in treatment of hypotension | 30 Jan, 2035 | Active |
| US9744209 | Vasopressin formulations for use in treatment of hypotension | 30 Jan, 2035 | Active |
| US9744239 | Vasopressin formulations for use in treatment of hypotension | 30 Jan, 2035 | Active |
| US9750785 | Vasopressin formulations for use in treatment of hypotension | 30 Jan, 2035 | Active |
| US9919026 | Vasopressin formulations for use in treatment of hypotension | 30 Jan, 2035 | Active |
| US9925233 | Vasopressin formulations for use in treatment of hypotension | 30 Jan, 2035 | Active |
| US9925234 | Vasopressin formulations for use in treatment of hypotension | 30 Jan, 2035 | Active |
| US9937223 | Vasopressin formulations for use in treatment of hypotension | 30 Jan, 2035 | Active |
| US9962422 | Vasopressin formulations for use in treatment of hypotension | 30 Jan, 2035 | Active |
| US9968649 | Vasopressin formulations for use in treatment of hypotension | 30 Jan, 2035 | Active |
| US9974827 | Vasopressin formulations for use in treatment of hypotension | 30 Jan, 2035 | Active |
| US9981006 | Vasopressin formulations for use in treatment of hypotension | 30 Jan, 2035 | Active |
| US8871779 | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds | 22 Nov, 2029 | Active |
| US8808737 | Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment | 21 Jun, 2027 | Active |
| US8338395 | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels | 08 May, 2027 | Active |
| US7718640 | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels | 14 Mar, 2027 | Active |
| US7776007 | Device for readying a needle free injector for delivery | 22 Nov, 2026 | Active |
| US7901385 | Casing | 31 Jul, 2026 | Active |
| US8062652 | Compositions and methods for treating precocious puberty | 16 Jun, 2026 | Active |
| US8241243 | Needleless injector drug capsule and a method for filling thereof | 25 Dec, 2025 | Active |
| US7320968 | Pharmaceutical composition | 18 Jan, 2025 | Active |
| US8287489 | Device for readying a needle free injector for delivery | 06 Dec, 2024 | Active |
| US7229636 | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery | 01 Aug, 2024 | Expired |
| US7879349 | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery | 01 Aug, 2024 | Expired |
| US8003353 | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery | 01 Aug, 2024 | Expired |
| US9415007 | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery | 28 Jul, 2024 | Expired |
| US7101576 | Nanoparticulate megestrol formulations | 22 Apr, 2024 | Expired |
| US9040088 | Nanoparticulate megestrol formulations | 22 Apr, 2024 | Expired |
| US9101540 | Nanoparticulate megestrol formulations | 22 Apr, 2024 | Expired |
| US9101549 | Nanoparticulate megestrol formulations | 22 Apr, 2024 | Expired |
| US9107827 | Nanoparticulate megestrol formulations | 22 Apr, 2024 | Expired |
| US7404489 | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery | 12 Mar, 2024 | Expired |
| US8940714 | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery | 26 Feb, 2024 | Expired |
| US8118771 | Needleless injector drug capsule and a method for filling thereof | 10 Aug, 2023 | Expired |
| US7608605 | Pharmaceutical composition | 21 Apr, 2023 | Expired |
| US7608606 | Pharmaceutical composition | 21 Apr, 2023 | Expired |
| US7608607 | Pharmaceutical composition | 21 Apr, 2023 | Expired |
| US7608608 | Pharmaceutical composition | 21 Apr, 2023 | Expired |
| US7608609 | Pharmaceutical composition | 21 Apr, 2023 | Expired |
| US7608610 | Pharmaceutical composition | 21 Apr, 2023 | Expired |
| US7935690 | Pharmaceutical composition | 21 Apr, 2023 | Expired |
| US8063029 | Pharmaceutical composition | 21 Apr, 2023 | Expired |
| US8178518 | Pharmaceutical composition | 21 Apr, 2023 | Expired |
| US8267903 | Casing | 18 Mar, 2023 | Expired |
| US7276250 | Sustained release formulations of oxymorphone | 04 Feb, 2023 | Expired |
| US8309112 | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same | 04 Feb, 2023 | Expired |
| US8329216 | Oxymorphone controlled release formulations | 04 Feb, 2023 | Expired |
| US8241244 | Needleless injector drug capsule and a method for filling thereof | 21 Nov, 2022 | Expired |
| US8491524 | Needleless injector drug capsule and a method for filling thereof | 21 Nov, 2022 | Expired |
| US8343130 | Needleless injector | 18 Oct, 2022 | Expired |
| US6592903 | Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate | 21 Sep, 2020 | Expired |
| US6319913 | Penetration enhancing and irritation reducing systems | 09 Nov, 2018 | Expired |
| US6579865 | Penetration enhancing and irritation reducing systems | 09 Nov, 2018 | Expired |
| US6280410 | Method of filling a drug capsule and article produced thereby | 27 Mar, 2017 | Expired |
| US6135979 | Spring-powered dispensing device for medical purposes | 21 Mar, 2017 | Expired |
| US6251091 | Needleless injector drug capsule and filling method | 09 Dec, 2016 | Expired |
| US5957886 | Spring-Powered dispensing device | 08 Mar, 2016 | Expired |
| US6174304 | Filling device for a needless injector cartridge | 13 Dec, 2015 | Expired |
| US6681810 | Filling device for a needleless injector cartridge | 13 Dec, 2015 | Expired |
| US5464864 | Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists | 07 Nov, 2015 | Expired |
| US5827871 | Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT1 agonist use thereof | 27 Oct, 2015 | Expired |
| US5891086 | Needle-less injector | 27 Jul, 2014 | Expired |
| US5637611 | Medicaments | 10 Jun, 2014 | Expired |
| US5616603 | Enantiomers of carbazole derivatives as 5-HT1 -like agonists | 01 Apr, 2014 | Expired |
| US5962501 | Enantiomer of carbazole derivative as 5-HT1-like agonists | 16 Dec, 2013 | Expired |
| US5662933 | Controlled release formulation (albuterol) | 09 Sep, 2013 | Expired |
| US5958456 | Controlled release formulation (albuterol) | 09 Sep, 2013 | Expired |
Latest Legal Activities on Endo Operations's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Endo Operations.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 08 Jul, 2024 | US8192722 |
|
Maintenance Fee Reminder Mailed
Critical
| 01 Jul, 2024 | US8309060 |
|
Expire Patent
Critical
| 17 Jun, 2024 | US8178518 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Jun, 2024 | US8338395 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Jun, 2024 | US10869845 (Litigated) |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 30 May, 2024 | US10869845 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 May, 2024 | US8329216 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Apr, 2024 | US8309122 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 22 Jan, 2024 | US8192722 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Jan, 2024 | US9415007 |
|
Maintenance Fee Reminder Mailed
Critical
| 01 Jan, 2024 | US8178518 (Litigated) |
|
Expire Patent
Critical
| 25 Dec, 2023 | US8063029 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Nov, 2023 | US9375478 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Oct, 2023 | US10653646 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 02 Aug, 2023 | US8114383 |
Endo Operations's Drug Patent Litigations
Endo Operations's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 22, 2014, against patent number US8329216. The petitioner Amneal Pharmaceuticals, LLC, challenged the validity of this patent, with Endo Pharmaceuticals, Inc. as the respondent. Click below to track the latest information on how companies are challenging Endo Operations's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8329216 | January, 2014 |
FWD Entered
(22 Jul, 2015)
| Endo Pharmaceuticals, Inc. | Amneal Pharmaceuticals, LLC |
| US8329216 | August, 2014 |
FWD Entered
(22 Jul, 2015)
| Endo Pharmaceuticals, Inc. | Amneal Pharmaceuticals, LLC |
Endo Operations Drug Patents' Oppositions Filed in EPO
Endo Operations drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 10, 2010, by Straus, Alexander. This opposition was filed on patent number EP07751984A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP05762243A | Jan, 2016 | Actavis Group PTC EHF | Revoked |
| EP07751984A | Aug, 2010 | Straus, Alexander | Revoked |
Endo Operations's Family Patents
Endo Operations Drug List
Given below is the complete list of Endo Operations's drugs and the patents protecting them.
1. Adrenalin
Adrenalin is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10653646 | Epinephrine compositions and containers |
21 Mar, 2039
(14 years from now)
| Active |
| US11083698 | Epinephrine compositions and containers |
21 Mar, 2039
(14 years from now)
| Active |
| US11207280 | Epinephrine compositions and containers |
21 Mar, 2039
(14 years from now)
| Active |
| US12133837 |
21 Mar, 2039
(14 years from now)
| Active | |
| US10130592 | Epinephrine formulations |
13 Mar, 2035
(10 years from now)
| Active |
| US9119876 | Epinephrine formulations |
13 Mar, 2035
(10 years from now)
| Active |
| US9295657 | Epinephrine formulations |
13 Mar, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adrenalin's drug page
2. Aveed
Aveed is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8338395 | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
08 May, 2027
(2 years from now)
| Active |
| US7718640 | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
14 Mar, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aveed's drug page
3. Ephedrine Sulfate
Ephedrine Sulfate is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10869845 | Ephedrine compositions and methods |
22 Jan, 2040
(15 years from now)
| Active |
| US12029710 | Ephedrine compositions and methods |
22 Jan, 2040
(15 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ephedrine Sulfate's drug page
4. Fortesta
Fortesta is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6319913 | Penetration enhancing and irritation reducing systems |
09 Nov, 2018
(6 years ago)
| Expired |
| US6579865 | Penetration enhancing and irritation reducing systems |
09 Nov, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fortesta's drug page
5. Frova
Frova is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5464864 | Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists |
07 Nov, 2015
(9 years ago)
| Expired |
| US5827871 | Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT1 agonist use thereof |
27 Oct, 2015
(9 years ago)
| Expired |
| US5637611 | Medicaments |
10 Jun, 2014
(10 years ago)
| Expired |
| US5616603 | Enantiomers of carbazole derivatives as 5-HT1 -like agonists |
01 Apr, 2014
(10 years ago)
| Expired |
| US5962501 | Enantiomer of carbazole derivative as 5-HT1-like agonists |
16 Dec, 2013
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Frova's drug page
Explore Our Curated Drug Screens
6. Megace Es
Megace Es is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7101576 | Nanoparticulate megestrol formulations |
22 Apr, 2024
(6 months ago)
| Expired |
| US9040088 | Nanoparticulate megestrol formulations |
22 Apr, 2024
(6 months ago)
| Expired |
| US9101540 | Nanoparticulate megestrol formulations |
22 Apr, 2024
(6 months ago)
| Expired |
| US9101549 | Nanoparticulate megestrol formulations |
22 Apr, 2024
(6 months ago)
| Expired |
| US9107827 | Nanoparticulate megestrol formulations |
22 Apr, 2024
(6 months ago)
| Expired |
| US6592903 | Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
21 Sep, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Megace Es's drug page
7. Nascobal
Nascobal is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7229636 | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
01 Aug, 2024
(3 months ago)
| Expired |
| US7879349 | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
01 Aug, 2024
(3 months ago)
| Expired |
| US8003353 | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
01 Aug, 2024
(3 months ago)
| Expired |
| US9415007 | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
28 Jul, 2024
(3 months ago)
| Expired |
| US7404489 | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
12 Mar, 2024
(8 months ago)
| Expired |
| US8940714 | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
26 Feb, 2024
(8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nascobal's drug page
8. Opana Er
Opana Er is protected by 7 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8871779 | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds |
22 Nov, 2029
(5 years from now)
| Active |
| US8808737 | Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment |
21 Jun, 2027
(2 years from now)
| Active |
| US7276250 | Sustained release formulations of oxymorphone |
04 Feb, 2023
(1 year, 9 months ago)
| Expired |
| US8309112 | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
04 Feb, 2023
(1 year, 9 months ago)
| Expired |
| US8329216 | Oxymorphone controlled release formulations |
04 Feb, 2023
(1 year, 9 months ago)
| Expired |
| US5662933 | Controlled release formulation (albuterol) |
09 Sep, 2013
(11 years ago)
| Expired |
| US5958456 | Controlled release formulation (albuterol) |
09 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Opana Er's drug page
9. Sumavel Dosepro
Sumavel Dosepro is protected by 16 patents, out of which 12 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7776007 | Device for readying a needle free injector for delivery |
22 Nov, 2026
(2 years from now)
| Active |
| US7901385 | Casing |
31 Jul, 2026
(1 year, 8 months from now)
| Active |
| US8241243 | Needleless injector drug capsule and a method for filling thereof |
25 Dec, 2025
(1 year, 1 month from now)
| Active |
| US8287489 | Device for readying a needle free injector for delivery |
06 Dec, 2024
(14 days from now)
| Active |
| US8118771 | Needleless injector drug capsule and a method for filling thereof |
10 Aug, 2023
(1 year, 3 months ago)
| Expired |
| US8267903 | Casing |
18 Mar, 2023
(1 year, 8 months ago)
| Expired |
| US8241244 | Needleless injector drug capsule and a method for filling thereof |
21 Nov, 2022
(2 years ago)
| Expired |
| US8491524 | Needleless injector drug capsule and a method for filling thereof |
21 Nov, 2022
(2 years ago)
| Expired |
| US8343130 | Needleless injector |
18 Oct, 2022
(2 years ago)
| Expired |
| US6280410 | Method of filling a drug capsule and article produced thereby |
27 Mar, 2017
(7 years ago)
| Expired |
| US6135979 | Spring-powered dispensing device for medical purposes |
21 Mar, 2017
(7 years ago)
| Expired |
| US6251091 | Needleless injector drug capsule and filling method |
09 Dec, 2016
(7 years ago)
| Expired |
| US5957886 | Spring-Powered dispensing device |
08 Mar, 2016
(8 years ago)
| Expired |
| US6174304 | Filling device for a needless injector cartridge |
13 Dec, 2015
(8 years ago)
| Expired |
| US6681810 | Filling device for a needleless injector cartridge |
13 Dec, 2015
(8 years ago)
| Expired |
| US5891086 | Needle-less injector |
27 Jul, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sumavel Dosepro's drug page
10. Supprelin La
Supprelin La is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8062652 | Compositions and methods for treating precocious puberty |
16 Jun, 2026
(1 year, 6 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Supprelin La's drug page
11. Testim
Testim is protected by 10 patents, out of which 9 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7320968 | Pharmaceutical composition |
18 Jan, 2025
(a month from now)
| Active |
| US7608605 | Pharmaceutical composition |
21 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US7608606 | Pharmaceutical composition |
21 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US7608607 | Pharmaceutical composition |
21 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US7608608 | Pharmaceutical composition |
21 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US7608609 | Pharmaceutical composition |
21 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US7608610 | Pharmaceutical composition |
21 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US7935690 | Pharmaceutical composition |
21 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US8063029 | Pharmaceutical composition |
21 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US8178518 | Pharmaceutical composition |
21 Apr, 2023
(1 year, 7 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Testim's drug page
12. Vasostrict
Vasostrict is protected by 14 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10010575 | Vasopressin formulations for use in treatment of hypotension |
30 Jan, 2035
(10 years from now)
| Active |
| US9375478 | Vasopressin formulations for use in treatment of hypotension |
30 Jan, 2035
(10 years from now)
| Active |
| US9687526 | Vasopressin formulations for use in treatment of hypotension |
30 Jan, 2035
(10 years from now)
| Active |
| US9744209 | Vasopressin formulations for use in treatment of hypotension |
30 Jan, 2035
(10 years from now)
| Active |
| US9744239 | Vasopressin formulations for use in treatment of hypotension |
30 Jan, 2035
(10 years from now)
| Active |
| US9750785 | Vasopressin formulations for use in treatment of hypotension |
30 Jan, 2035
(10 years from now)
| Active |
| US9919026 | Vasopressin formulations for use in treatment of hypotension |
30 Jan, 2035
(10 years from now)
| Active |
| US9925233 | Vasopressin formulations for use in treatment of hypotension |
30 Jan, 2035
(10 years from now)
| Active |
| US9925234 | Vasopressin formulations for use in treatment of hypotension |
30 Jan, 2035
(10 years from now)
| Active |
| US9937223 | Vasopressin formulations for use in treatment of hypotension |
30 Jan, 2035
(10 years from now)
| Active |
| US9962422 | Vasopressin formulations for use in treatment of hypotension |
30 Jan, 2035
(10 years from now)
| Active |
| US9968649 | Vasopressin formulations for use in treatment of hypotension |
30 Jan, 2035
(10 years from now)
| Active |
| US9974827 | Vasopressin formulations for use in treatment of hypotension |
30 Jan, 2035
(10 years from now)
| Active |
| US9981006 | Vasopressin formulations for use in treatment of hypotension |
30 Jan, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vasostrict's drug page